In non-alcoholic fatty liver disease, SalB reduces the expression levels of NF-κB p65, IL-6, and TNF-α in the liver, mitigating liver damage [28]. This evidence concerns the gene IL6 and metabolic dysfunction-associated steatotic liver disease.